Medasense Biometrics Ltd.


Therapeutic Area(s):
Pain Management
Company Status:
Regulatory Approval

Company at a Glance

Medasense meets the clinical need to objectively assess pain.
Pain affects quality of life for millions of patients. Unmanaged pain delays recovery, increases morbidity and mortality, and overburdens healthcare resources. Objective pain monitoring, which is believed to become a standard of care, will revolutionize pain management by enabling optimization and personalization of pain treatment and thus, contribute to better clinical outcomes.
Medasense’s breakthrough platform technology is based on artificial intelligence algorithms and signal processing. It enables objective, non-invasive, and continuous assessment and monitoring of pain level.
The patented technology was validated in trials with hundreds of patients, and was reported to be superior to existing technologies or methodologies by the most important scientific journals.
Medasense’s flagship product is PMD-200™: An intraoperative pain monitoring system for anesthetized patients that are unable to communicate their pain.

Technology & Product(s)

PMD-200™ is an intraoperative pain monitoring system for anesthetized patients.
The need: During general anesthesia, a patient’s body reacts to painful stimuli – nociception. This is currently hard for clinicians to evaluate and consequently, patients may be given too little or too much pain medications.
This may cause various clinical complications that extend post-op recovery time and length of stay, increase costs and affect patient satisfaction.
The solution: PMD-200™ objectively and reliably quantifies pain (nociception). The system helps to guide the analgesic administration, and enable faster response time through earlier detection of an undesired trend.
How it works: Medasense’s technology combines a non-invasive sensing unit and a monitor:
Sensing – a non-invasive finger probe continuously acquires pain-related physiological signals through four sensors.
Analyzing – artificial intelligence algorithms and signal processing identify and analyze changes in painrelated physiological patterns.
Grading – the information is presented on the PMD-200™ bedside monitor as a real time, personalized index – the NoL™ (Nociception level Index) that varies from 0 (no pain) to 100 (extreme pain).

Goals

Objectives: Launch of PMD-200 pain monitoring system for operating rooms. Find distributors.
Target businesses: Hospitals, Distributors, and Health Insurance.
Target Countries: UK, Germany, France, Netherlands, Belgium, Austria, Switzerland, Denmark, Sweden, Norway, USA.